Grant: Fellowship - Priority Announcement - Inflammatory Bowel Disease
University of Ottawa
$45,000.00
Identifying bacterial taxa and/or metabolic pathways that provide mechanistic insight into inflammatory bowel disease pathogenesis by characterizing the gut microbiota composition of pediatric inflammatory bowel disease patients
EF 2013-14
Résumé
There are over 200,000 Canadians living with inflammatory bowel disease (IBD) with 10,000 new cases diagnosed every year. IBD is a chronic incurable gastrointestinal disease and is comprised of two main subtypes: Crohn's disease (CD) and ulcerative colitis (UC). Canada has one of the highest incidence rates of IBD in the world and approximately 25% of these cases are diagnosed in childhood. There is no medical cure for IBD and the cause remains uncertain. A prevailing hypothesis is that the composition of the gut microbiota can influence the onset of IBD by influencing cellular metabolism at the site of inflammation. We will test this hypothesis by collecting characterizing the microbiota of IBD patients and determining whether the microbiota of IBD patients differs from healthy controls. Moreover, we will determine the metabolic potential of the diseased microbiota to determine whether the presence of specific metabolic pathways would explain the symptoms seen in IBD patients. These results will reveal the microbes and metabolic pathways involved in IBD and enable future hypothesis-driven research on IBD pathogenesis.
In addition, the routine diagnostics used to currently differentiate IBD subtypes are inadequate for pediatric patients. As the treatments and responses to medical therapies differ between CD and UC, there is an urgent need for biomarkers to differentiate between CD and UC. We will use the data generated from our research to develop clinically relevant biomarkers. Objective measures to quickly monitor disease activity and sub-type, such as biomarker testing, will allow physicians to further optimize treatment strategies and to risk-stratify patients at time of diagnosis. These treatment improvements would promote the ultimate clinical goal of reaching deep and long-lasting remission in most patients.
Programme
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
302330
Name
Butcher James
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Crohn's and Colitis Canada (Toronto, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identifying bacterial taxa and/or metabolic pathways that provide mechanistic insight into inflammatory bowel disease pathogenesis by characterizing the gut microbiota composition of pediatric inflammatory bowel disease patients
Programtype2
Fellowship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement - Inflammatory Bowel Disease
Keyworddelim
Biomarker Discovery; Crohn'S Disease; Gut Microbiota; Inflammatory Bowl Disease; Ulcerative Colitis
Abstract
There are over 200,000 Canadians living with inflammatory bowel disease (IBD) with 10,000 new cases diagnosed every year. IBD is a chronic incurable gastrointestinal disease and is comprised of two main subtypes: Crohn's disease (CD) and ulcerative colitis (UC). Canada has one of the highest incidence rates of IBD in the world and approximately 25% of these cases are diagnosed in childhood. There is no medical cure for IBD and the cause remains uncertain. A prevailing hypothesis is that the composition of the gut microbiota can influence the onset of IBD by influencing cellular metabolism at the site of inflammation. We will test this hypothesis by collecting characterizing the microbiota of IBD patients and determining whether the microbiota of IBD patients differs from healthy controls. Moreover, we will determine the metabolic potential of the diseased microbiota to determine whether the presence of specific metabolic pathways would explain the symptoms seen in IBD patients. These results will reveal the microbes and metabolic pathways involved in IBD and enable future hypothesis-driven research on IBD pathogenesis.
In addition, the routine diagnostics used to currently differentiate IBD subtypes are inadequate for pediatric patients. As the treatments and responses to medical therapies differ between CD and UC, there is an urgent need for biomarkers to differentiate between CD and UC. We will use the data generated from our research to develop clinically relevant biomarkers. Objective measures to quickly monitor disease activity and sub-type, such as biomarker testing, will allow physicians to further optimize treatment strategies and to risk-stratify patients at time of diagnosis. These treatment improvements would promote the ultimate clinical goal of reaching deep and long-lasting remission in most patients.
Competitiondate
201311
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Butcher, James
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $45,000~ $0~